drug · small molecule

DELSTRIGO

updated 3mo ago

by $MRK Merck & Co., Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.

targets

Human immunodeficiency virus type 1 reverse transcriptase

all catalysts(0)

nothing on the calendar yet

Trials studying DELSTRIGO

phase1Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Womencompletedn=7
phase4Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteerscompletedn=20
phase2Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)recruitingn=84
EP1Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIVcompletedn=26
phase4Efficacy and Safety of Doravirine in the Rapid Initiationnot yet recruitingn=100
phase3DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infectionrecruitingn=610
—Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartumcompletedn=205
phase2DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)recruitingn=32

more trials →

News(0)

no news has mentioned this drug yet

brand

DELSTRIGO

trade names

Doravirine component of delstrigo, Pifeltro

generic

DORAVIRINE

MOA

12.1 Mechanism of Action DELSTRIGO is a fixed-dose combination of the antiretroviral drugs doravirine, lamivudine, and TDF [see Microbiology (12.4) ].

indication

1 INDICATIONS AND USAGE DELSTRIGO ® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO [see Clinical Studies (14) ] . DELSTRIGO is a three-drug combination of doravirine (a non-nucleoside reverse transcriptase inhibitor [NNRTI]), lamivudine, and tenofovir disoproxil fumarate (both nucleoside analogue reverse transcriptase inhibitors) and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no antiretroviral treatment history, OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO. ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 48m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

DELSTRIGO

updated 3mo ago

by $MRK Merck & Co., Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.

targets

Human immunodeficiency virus type 1 reverse transcriptase

all catalysts(0)

nothing on the calendar yet

Trials studying DELSTRIGO

phase1Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Womencompletedn=7
phase4Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteerscompletedn=20
phase2Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)recruitingn=84
EP1Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIVcompletedn=26
phase4Efficacy and Safety of Doravirine in the Rapid Initiationnot yet recruitingn=100
phase3DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infectionrecruitingn=610
—Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartumcompletedn=205
phase2DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)recruitingn=32

more trials →

News(0)

no news has mentioned this drug yet

brand

DELSTRIGO

trade names

Doravirine component of delstrigo, Pifeltro

generic

DORAVIRINE

MOA

12.1 Mechanism of Action DELSTRIGO is a fixed-dose combination of the antiretroviral drugs doravirine, lamivudine, and TDF [see Microbiology (12.4) ].

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 48m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

DELSTRIGO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying DELSTRIGO

News(0)

Report a data issue

comments(0)

DELSTRIGO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying DELSTRIGO

News(0)

Report a data issue

comments(0)